| Literature DB >> 29735472 |
Paul Wicks1, Eileen Mack Thorley1, Kristina Simacek1, Christopher Curran1, Cathy Emmas2.
Abstract
BACKGROUND: Launched in 2006 for patients with amyotrophic lateral sclerosis, PatientsLikeMe is an online community offering patient-reported outcomes, symptom tracking, and social features. Every member of the site can see all the data reported by every other member, view aggregated reports, identify "patients like them," and learn about treatment options in order to live better with their condition. In previous studies, members reported benefits such as improved condition knowledge, increased medication adherence, and better management of side effects. However, the site evolved in 2011 from condition-specific "vertical" communities consisting only of people with the same disease to a "generalized platform," in which every patient could connect with every other patient regardless of condition and with generic, rather than condition-specific, data tools. Some, but not all, communities received further custom tracking tools.Entities:
Keywords: health care; online health community; online support group; personal health records; personal monitoring; personal tracking; self-help devices; social support; technology
Mesh:
Year: 2018 PMID: 29735472 PMCID: PMC5962830 DOI: 10.2196/jmir.9909
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Experience of a hypothetical user before and after platform generalization. Multiple sclerosis (MS) and major depressive disorder (MDD) have community upgrades whereas type 2 diabetes (T2D) does not. MSRS: multiple sclerosis rating scale; N/A: not applicable; PLM QOL: PatientsLikeMe Quality of Life Questionnaire; PRO: patient reported outcome.
Figure 2Participant flow.
Demographics of respondents and nonrespondents. IQR: interquartile range.
| Characteristic | Responders (n=7434) | Nonresponders (n=370,191) | ||
| 7419 | 321,886 | <.001b | ||
| Mean (SD) | 54 (12) | 48 (14) | ||
| Median (IQR) | 54 (46-62) | 48 (38-58) | ||
| .61 | ||||
| Female | 5290 (71.16) | 232,260 (71.60) | ||
| Male | 2059 (27.70) | 92,111 (28.39) | ||
| Prefer to skip | 0 | 21 (<0.01) | ||
| <.001 | ||||
| White | 6106 (86.59) | 163,857 (80.65) | ||
| Black | 302 (4.28) | 9996 (4.92) | ||
| Mixed race | 291 (4.13) | 7591 (3.74) | ||
| Asian | 99 (1.40) | 8653 (4.26) | ||
| Native American | 90 (1.28) | 2175 (1.07) | ||
| Hawaiian | 6 (<0.01) | 514 (0.25) | ||
| Prefer to skip | 158 (2.24) | 10,397 (5.12) | ||
| <.001 | ||||
| High school grad or less | 898 (14.90) | 18,784 (19.51) | ||
| Some college | 2365 (39.25) | 36,172 (37.58) | ||
| College graduate | 1565 (25.97) | 22,881 (23.77) | ||
| Post graduate | 1132 (18.79) | 15,344 (15.94) | ||
| Prefer to skip | 66 (1.10) | 3080 (3.20) | ||
| <.001 | ||||
| Medicare | 1696 (28.03) | 15,518 (16.27) | ||
| Employer | 1802 (29.78) | 31,994 (33.54) | ||
| Medicaid | 589 (9.73) | 8412 (8.82) | ||
| National | 574 (9.49) | 10,691 (11.21) | ||
| Direct | 514 (8.49) | 8066 (8.46) | ||
| Veterans Affairs | 153 (2.53) | 1890 (1.98) | ||
| Military | 115 (1.90) | 1729 (1.81) | ||
| Indian Health Service | 2 (<0.01) | 108 (0.11) | ||
| Other | 97 (1.60) | 1949 (2.04) | ||
| None | 351 (5.80) | 8580 (8.99) | ||
| Prefer to skip | 158 (2.61) | 6451 (6.76) | ||
aP values from t test for age and chi-square test for categorical variables.
bSatterthwaite method reported due to unequal variances.
Health utilization and clinical characteristics of survey respondents (N=7434). IQR: interquartile range.
| Characteristic | Value | |
| Excellent | 198 (2.66) | |
| Very good | 968 (13.02) | |
| Good | 2596 (34.92) | |
| Fair | 2567 (34.53) | |
| Poor | 1105 (14.86) | |
| A primary care physician | 2325 (31.28) | |
| An internist at a hospital | 101 (1.36) | |
| A specialist in my condition | 4456 (59.94) | |
| I don’t see a physician | 278 (3.74) | |
| I don’t know | 183 (2.46) | |
| Prefer to skip | 91 (1.22) | |
| Extremely dissatisfied | 433 (5.82) | |
| Very dissatisfied | 527 (7.09) | |
| Dissatisfied | 1013 (13.63) | |
| Somewhat satisfied | 2326 (31.29) | |
| Satisfied | 1537 (20.68) | |
| Very satisfied | 817 (10.99) | |
| Extremely satisfied | 397 (5.34) | |
| Does not apply | 384 (5.17) | |
| Emergency department visits | 1.26 (3.52), 0 (0-1) | |
| Overnights in the hospital | 2.41 (10.66), 0 (0-1) | |
| Separate hospital stays | 1.26 (6.97), 0 (0-1) | |
| Never/rarely | 2614 (35.16) | |
| Once in a while | 2211 (29.74) | |
| Sometimes | 1608 (21.63) | |
| Usually | 514 (6.91) | |
| All the time | 295 (3.97) | |
| Does not apply | 192 (2.58) | |
Patient Activation Measure (PAM) distribution among survey respondents (N=7434).a
| PAM level | Description | n (%) |
| Level 1 | Does not feel in charge of their own health and care. Managing health is overwhelming for them with all of life’s other challenges. Lacks confidence in their ability to manage health. Has few problem-solving skills and poor coping skills. They may not be very aware of own behavior. | 1858 (24.99) |
| Level 2 | May lack basic knowledge about their condition, treatment options, and/or self-care. Have little experience or success with behavior change. Look to their doctor to be the one in charge. Low confidence in their ability to manage health. | 1449 (19.49) |
| Level 3 | Have the basic facts of their conditions and treatments. Some experience and success in making behavioral changes. Some confidence in handling limited aspects of their health | 2639 (35.50) |
| Level 4 | Have made most of the necessary behavior changes, but may have difficulty maintaining behaviors over time or during times of stress | 1312 (17.65) |
aA total of 176 individuals are missing due to selection of the “I prefer to skip” option.
Perceived benefits among all survey respondents (N=7434).
| Benefit | Respondents, n (%) | ||||||||||||
| Total survey | With community | Without community | |||||||||||
| How your condition(s) might affect you? | 4530 (66.91) | 2987 (71.05) | 918 (59.11) | <.001 | |||||||||
| What might help you live better with your condition(s)? | 4247 (62.92) | 2805 (66.77) | 852 (54.97) | <.001 | |||||||||
| Treatment side effects? | 4182 (60.59) | 2747 (64.20) | 854 (53.58) | <.001 | |||||||||
| Available treatments? | 4143 (60.06) | 2765 (64.69) | 819 (51.32) | <.001 | |||||||||
| Important factors in making decisions about treatments? | 3919 (57.52) | 2538 (60.40) | 808 (51.04) | <.001 | |||||||||
| What might help you get better? | 3339 (50.37) | 2159 (52.76) | 664 (43.40) | <.001 | |||||||||
| How to deal with other problems in your life (eg, stress, work, money) that may be caused by your condition(s)? | 3250 (47.86) | 2102 (49.94) | 679 (43.30) | <.001 | |||||||||
| Had better conversations with your health care professionals? | 3592 (51.62) | 2344 (54.61) | 762 (47.24) | <.001 | |||||||||
| Managed your symptoms better? | 3179 (45.64) | 2131 (49.51) | 634 (39.28) | <.001 | |||||||||
| Been better at taking your medication? | 2251 (33.74) | 1437 (34.94) | 475 (30.55) | .14 | |||||||||
| Tried a new way to manage side effects? | 2089 (29.79) | 1374 (32.73) | 440 (27.01) | <.001 | |||||||||
| Asked to see a specialist doctor? | 1699 (24.79) | 1011 (24.06) | 411 (25.77) | >.99 | |||||||||
| Started a new treatment? | 1046 (14.71) | 692 (15.77) | 196 (11.90) | .02 | |||||||||
| Stopped a treatment? | 993 (13.91) | 651 (14.80) | 220 (13.27) | .09 | |||||||||
| Changed your doctor? | 899 (12.59) | 546 (12.38) | 220 (13.34) | >.99 | |||||||||
aP values adjusted using Bonferroni correction.
bPercentages calculated out of valid nonmissing data and after removal of “does not apply” responses. A range of approximately 3% to 10% were observed across benefit questions.
Distribution of conditions most frequently represented in the survey, ordered by condition group then primary condition (N=6264).a IQR: interquartile range.
| Patient-reported primary condition | Condition group | n (%) | Mean (SD) | Median (IQR) |
| Diabetes type 2 | Cardiovascular and metabolic diseases | 174 (2.78) | 6.3 (3.9) | 7 (3-9) |
| Fibromyalgia | Fibromyalgia (other) | 668 (10.66) | 6.5 (4.0) | 7 (3-10) |
| Crohn’s disease | Inflammation and autoimmunity | 49 (0.78) | 5.0 (4.2) | 5 (1-8) |
| Rheumatoid arthritis | Inflammation and autoimmunity | 128 (2.04) | 6.4 (4.1) | 7 (3-9) |
| Systemic lupus erythematosus | Inflammation and autoimmunity | 271 (4.33) | 6.0 (4.0) | 6 (2-9) |
| Bipolar disorder | Mental and behavioral health | 245 (3.91) | 6.1 (4.1) | 7 (2-10) |
| Bipolar I disorder | Mental and behavioral health | 96 (1.53) | 6.9 (4.5) | 7 (3-10) |
| Bipolar II disorder | Mental and behavioral health | 130 (2.08) | 6.2 (4.0) | 7 (3-10) |
| Complex post-posttraumatic stress disorder | Mental and behavioral health | 54 (0.86) | 6.5 (4.4) | 7 (3-10) |
| Major depressive disorder | Mental and behavioral health | 308 (4.92) | 5.7 (3.9) | 6 (2-8) |
| Posttraumatic stress disorder | Mental and behavioral health | 232 (3.70) | 6.4 (4.1) | 7 (3-9) |
| Traumatic brain injury | Mental and behavioral health | 122 (1.95) | 6.3 (4.3) | 7 (3-10) |
| Myalgic encephalomyelitis/chronic fatigue syndrome | Myalgic encephalomyelitis/chronic fatigue syndrome (other) | 62 (0.99) | 5.1 (4.0) | 5 (1-8) |
| Amyotrophic lateral sclerosis | Neurologic | 281 (4.49) | 5.8 (3.6) | 6 (3-9) |
| Epilepsy | Neurologic | 109 (1.74) | 7.2 (4.5) | 8 (4-11) |
| Multiple sclerosis | Neurologic | 1005 (16.04) | 6.5 (3.9) | 7 (3-10) |
| Parkinson’s disease | Neurologic | 468 (7.47) | 6.2 (4.1) | 7 (3-9) |
| Lung cancer | Oncology | 98 (1.56) | 5.8 (4.0) | 6 (3-9) |
| Multiple myeloma | Oncology | 93 (1.48) | 4.9 (3.9) | 5 (1-8) |
| Idiopathic pulmonary fibrosis | Respiratory | 150 (2.39) | 6.2 (3.8) | 6 (3-9) |
aPrimary condition not reported and/or profile data unavailable for n=1170 patients.
Site use-related predictors of patient-perceived health benefits in the Impact Survey: univariate and multivariate models. Ref: reference group.
| Independent variables | Univariate models | Multivariate models | |||||||
| Dependent variable: total number of benefits (out of 15) | Dependent variable: total number of benefits (out of 15) | Benefits related to knowledge/understanding of one’s condition (out of 7) | Benefits related to treatment/management of one’s condition (out of 8) | ||||||
| β | RRa | β | RRa | RR | RR | ||||
| 18-39 | 0.12 | <.001 | 1.13 | -0.02 | 0.10 | 0.98 | 1.00 | 0.97 | |
| 40-55 | 0.09 | <.001 | 1.10 | -0.14 | <.001 | 1.12 | 0.91 | 0.85 | |
| ≥55 | 0 | — | Ref | 0 | — | Ref | Ref | Ref | |
| Male | 0 | — | Ref | 0 | — | Ref | Ref | Ref | |
| Female | 0.07 | <.001 | 1.08 | 0.07 | <.001 | 1.07 | 1.04 | 1.16 | |
| Tenure at baselinec | 0.02 | <.001 | 1.02 | 0.02 | <.001 | 1.02 | 1.02 | 1.02 | |
| None | 0 | — | Ref | 0 | — | Ref | Ref | Ref | |
| Customized | 0.16 | <.001 | 1.17 | 0.19 | <.001 | 1.21 | 1.24 | 1.13 | |
| Level 1 | 0 | — | Ref | 0 | — | Ref | Ref | Ref | |
| Level 2 | 0.15 | <.001 | 1.16 | 0.14 | <.001 | 1.15 | 1.21 | 1.06 | |
| Level 3 | 0.21 | <.001 | 1.24 | 0.21 | <.001 | 1.23 | 1.32 | 1.12 | |
| Level 4 | 0.25 | <.001 | 1.29 | 0.25 | <.001 | 1.29 | 1.42 | 1.13 | |
| Low engagement | 0 | — | Ref | 0 | — | Ref | Ref | Ref | |
| Mod-high engagement | 0.13 | <.001 | 1.14 | 0.10 | <.001 | 1.11 | 1.05 | 1.19 | |
| Cardiovascular and metabolic diseases | 0.04 | .10 | 1.04 | 0.18 | <.001 | 1.19 | 1.22 | 1.07 | |
| Infectious disease | –0.09 | .08 | 0.91 | –0.09 | .08 | 0.91 | 0.87 | 0.98 | |
| Inflammation and autoimmunity | –0.04 | .03 | 0.96 | –0.01 | .52 | 0.99 | 1.03 | 0.89 | |
| Mental and behavioral health | 0.07 | <.001 | 1.07 | 0.05 | .002 | 1.05 | 1.03 | 1.05 | |
| Neurologic | 0.07 | <.001 | 1.07 | 0.01 | .58 | 1.01 | 1.08 | 0.89 | |
| Oncology | –0.19 | <.001 | 0.82 | –0.07 | .006 | 0.93 | 1.03 | 0.74 | |
| Respiratory | 0.05 | .07 | 1.05 | 0.10 | .002 | 1.10 | 1.15 | 1.03 | |
| Other | 0 | — | Ref | 0 | — | Ref | Ref | Ref | |
aRelative risk (RR) greater than 1 represents a greater chance (“risk”) of an additional benefit compared to the reference category.
bRepresentation of the survey population in the category 18-24 years was quite low (2%) and thus was combined with the category 25-39 years to create the 18-39 years category. As seen in Table 1, the mean age in the population was 54.
cTenure at baseline variable converted to years (from days) for interpretation purposes.